الفهرس 
Overexpression of Cancerous Inhibitor of PP2A (CIP2A) in acute myeloid leukemia
INDEXOnly 14 pages are availabe for public view
 |  | from | 172 |  |  |
| | | from | 172 | | |
Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy that involves different molecules and signaling pathways. AML is the commonest type of leukemia in adults. It is the 6th leading cause of cancer related death in males’ worldwide. In Egypt, AML is considered to be the most common hematological malignancy comprising 37% of all hematological malignancies. PP2A is a major serine/threonine phosphatase and tumor suppressor that negatively regulates numerous signal transduction pathways involved in cell proliferation, differentiation and survival. CIP2A is identified as endogenous inhibitor of PP2A. CIP2A inhibits PP2A-mediated dephosphorylation of the oncogene kinase c-MYC in human malignancies. CIP2A is over-expressed in several human malignancies including hematologic malignancies. CIP2A over expression was shown to be a recurrent event in cytogenetic normal AML patients with a poor prognostic impact on the overall survival of these casesIn our study we measured the level of CIP2A expression by quantitative real time PCR (RT-PCR) in BM samples of 174 de-novo cytogenetically normal AML patients. We evaluated their level of expression in relation to other prognostic factors, response to treatment and survival